Neuphoria Therapeutics Inc. (NEUP): Total Assets
$28.71M
As of 2026-06-30
+0.2%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $28.71M | +0.4% | 2026-09-18, Balance as of period end |
| 2025-06-30 | $28.59M | +3.4% | 2026-09-18, Balance as of period end |
| 2024-06-30 | $27.65M | -3.2% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $28.56M | n/a | 2024-09-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $28.71M | +0.4% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $10.26M | -59.9% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $34.75M | +60.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $48.56M | -42.4% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $8.75M | -11.7% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $32.47M | +46.9% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $7.02M | -35.2% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $5.37M | -6.8% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $81.29M | +204.1% |
Compare NEUP, LGVN, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗